Alphamab Oncology Announced Innovative Bispecific Antibody Coupling Drug JSKN016 Clinical Study Accepted by CDE

On January 9, 2024 Alphamab Oncology (stock code: 9966.HK) reported an application for clinical trial of JSKN016, a new generation of bispecific antibody ADC drug, was officially accepted by CDE and will carry out clinical research on the treatment of advanced malignant solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JSKN016 can simultaneously target HER3 (Human epidermal growth factor receptor 3) and TROP2 (Trophoblast cell surface antigen 2, Human trophoblastic surface antigen 2). After binding with TROP2 or HER3 on the surface of tumor cells, JSKN016 enters the lysosome through target-mediated endocytosis, releasing cytotoxic topoisomerase I inhibitor (TOPIi), and then inducing tumor cell apoptosis. In addition, the inhibitor can penetrate the cell membrane and enter the antigen-negative tumor cells to exert bystander effect.These effects can effectively inhibit the growth of tumor cells.

This is the first global clinical study of JSKN016 to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of JSKN016 in Chinese subjects with advanced malignant solid tumors.

About JSKN016

JSKN016 is a bispecific antibody conjugated drug (ADC) targeting HER3 and TROP2, which is developed inhouse with proprietary Glycan-specific conjugation platform. JSKN016 can induce apoptosis of TROP2 or HER3 positive tumor cells, and penetrate the cell membrane into antigen-negative tumor cells to exert bystander effect, thus effectively inhibiting the growth of tumor cells. The clinical study of JSKN016 for the treatment of advanced malignant solid tumors has been accepted by the CDE.

(Press release, Alphamab, JAN 9, 2024, View Source [SID1234657018])